Zheng Zhou

Dr. Zheng Zhou


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2024 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
JWJiaxing Wang
Jiaxing Wang
CJChengyue Ji
Chengyue Ji
WYWu Ye
Wu Ye
YRYuluo Rong
Yuluo Rong
XGXuhui Ge
Xuhui Ge
CWcai weihua
cai weihua
Improving the function of the blood–spinal cord barrier (BSCB) benefits the functional recovery of mice following spinal cord injury (SCI). The death of endothelial cells and disruption of the BSCB at the injury site contribute to secondary damage, and the ubiquitin–proteasome system is involved in regulating protein function. However, little is known about the regulation of deubiquitinated enzymes in endothelial cells and their effect on BSCB function after SCI. We observed that Sox17 is predominantly localized in endothelial cells and is significantly upregulated after SCI and in LPS-treated brain microvascular endothelial cells. In vitro Sox17 knockdown attenuated endothelial cell proliferation, migration, and tube formation, while in vivo Sox17 knockdown inhibited endothelial regeneration and barrier recovery, leading to poor functional recovery after SCI. Conversely, in vivo overexpression of Sox17 promoted angiogenesis and functional recovery after injury. Additionally, immunoprecipitation-mass spectrometry revealed the interaction between the deubiquitinase UCHL1 and Sox17, which stabilized Sox17 and influenced angiogenesis and BSCB repair following injury. By generating UCHL1 conditional knockout mice and conducting rescue experiments, we further validated that the deubiquitinase UCHL1 promotes angiogenesis and restoration of BSCB function after injury by stabilizing Sox17. Collectively, our findings present a novel therapeutic target for treating SCI by revealing a potential mechanism for endothelial cell regeneration and BSCB repair after SCI.

12 February 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
XWXiaokun Wang
Xiaokun Wang
GZGeliang Zhou
Geliang Zhou
JXJunjun Xiong
Junjun Xiong
WYWu Ye
Wu Ye
YGYu Gao
Yu Gao
ZZZheng Zhou
Zheng Zhou
Background: Spinal cord injury (SCI) is a severe condition leading to significant disability and high mortality. The role of the secreted phosphoprotein 1 (SPP1) signaling pathway in SCI, which is quickly activated after injury, is critical for intercellular communication but remains poorly understood. Aims: This study aimed to explore the function and regulatory mechanisms of the SPP1 signaling pathway in SCI and investigate its potential as a therapeutic target for improving functional recovery after injury. Materials and Methods: Single‐cell RNA sequencing (scRNA‐seq) was employed to identify ligands and receptors of the SPP1 signaling pathway, particularly in microglia/macrophages. Recombinant SPP1 (rSPP1) was used in vitro and in vivo to assess its effects on neuronal maturation, mitochondrial energy in axons, and functional recovery after SCI. Pseudotime analysis was conducted to examine the role of Spp1 in microglial activation and proliferation. DNA‐pulldown and in vitro experiments were performed to investigate the upstream regulatory proteins of Spp1 . Results: The SPP1 signaling pathway is primarily localized in microglia after SCI, with rSPP1 promoting neuronal maturation and enhancing mitochondrial function in axons. Injection of rSPP1 into the injured spinal cord resulted in significant improvement in functional recovery. Pseudotime analysis indicated that Spp1 is involved in the activation and proliferation of microglia. Histone H4 lysine 12 lactylation (H4K12la) was found to promote the transcription of Spp1 in reprogrammed microglia postinjury. Discussion: Our findings reveal a novel regulatory mechanism involving Spp1 in SCI, particularly its role in microglial activation, mitochondrial function, and glycolytic reprogramming. This new insight provides a deeper understanding of its contribution to the injury response. Conclusion: This study uncovers a previously unreported mechanism of Spp1 in SCI, offering a potential therapeutic target for SCI.

1 January 2025 in Biomaterials Research
Verified
Journal Article
Open access
YLYongjun Luo
Yongjun Luo
XZXiao Zhang
Xiao Zhang
QLQian Luo
Qian Luo
LWLiang Wu
Liang Wu
SGShubo Gu
Shubo Gu
ZZZheng Zhou
Zheng Zhou
The use of injectable hydrogels represents a viable approach for enhancing neural repair and promoting functional restoration after spinal cord trauma. Nevertheless, the current performance of these materials is not yet optimal and further optimization is necessary. Engineering a cell-free hydrogel delivery system with sustained anti-inflammatory capacity is of great relevance for advancing therapeutic strategies in spinal cord injury (SCI). Here, we fabricated a biomimetic hydrogel incorporating spermidine to modulate the post-injury immune microenvironment. The material was constructed by photocrosslinking aldehyde-modified methacrylated hyaluronic acid (AHAMA) through dynamic Schiff base chemistry, enabling controlled and prolonged spermidine release. This hydrogel demonstrated expedited gelation kinetics coupled with stable and exceptional mechanical properties. In addition, the cell-free AHAMA hydrogels have substantially enhanced the cellular–matrix interactions and facilitated neuronal integration. Furthermore, the spermidine-loaded hydrogel exerted potent immunomodulatory effects by suppressing M1 macrophage (classically activated macrophage) polarization through activation of STAT1 (signal transducer and activator of transcription 1) signaling axis. In vivo assessments demonstrated enhanced neuroregeneration and axonal elongation at the lesion site, which translated into marked improvements in locomotor function in the murine SCI model. Collectively, the combination of sustained spermidine release with a bioinspired, cell-free AHAMA hydrogel scaffold offers an effective therapeutic approach to modulate inflammation and enhance tissue repair in the injured spinal cord environment.

1 January 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
CSChenyuan Shi
Chenyuan Shi
CYChao Yuan
Chao Yuan
YHYifei Hao
Yifei Hao
ZZZheng Zhou
Zheng Zhou
YZYigang Zhang
Yigang Zhang
Background: The presence of fatty liver (FL) has been suggested to influence the incidence of colorectal cancer (CRC). This study aimed to evaluate the predictive utility of six alternative indices of FL—namely, liver fat percentage (PLF), lipid accumulation product (LAP), hepatic steatosis index (HSI), United States fatty liver index (USFLI), fatty liver index (FLI), and Zhejiang University index (ZJU)—in assessing the risk of CRC. We aimed to determine their effectiveness in predicting CRC risk by comparing these surrogate indices. Methods: Data for this study were derived from the National Health and Nutrition Examination Survey (NHANES) conducted between 2003 and 2018, focusing on adults over 20 years old. The six FLIs were calculated using established methodologies outlined in prior research. To identify key variables, the Boruta algorithm was employed. The relationships between FLIs and CRC risk were assessed using multivariable logistic regression, generalized linear models (GLMs), and restricted cubic spline (RCS) models. Additionally, subgroup analyses were performed to investigate the effects of potential confounders. Results: Among the 16,250 individuals surveyed, 96 were diagnosed with CRC. Those with CRC exhibited significantly higher levels of PLF (4.65 vs. 3.31, P=0.004), LAP (55.63 vs. 42.34, P=0.04), USFLI (23.22 vs. 17.83, P<0.001), and FLI (58.16 vs. 50.86, P=0.048) compared to individuals without CRC. Multivariate logistic regression and RCS analyses indicated that, of the six indices, only USFLI was significantly associated with an increased risk of CRC. Notably, further stratification of USFLI revealed that this association was consistently stronger in individuals aged over 65 years [odds ratio (OR) =1.023; 95% confidence interval (CI): 1.005–1.041; P=0.01] and among non-smokers (OR =1.018; 95% CI: 1.003–1.033; P=0.02) after adjusting for multiple confounders. Conclusions: The USFLI index demonstrated a more significant association with the risk of CRC compared to the other five alternative FLIs, highlighting its potential utility in predicting CRC risk in clinical settings.